FREE NEJM E-TOC    HOME   |   SUBSCRIBE   |   CURRENT ISSUE   |   PAST ISSUES   |   COLLECTIONS   |   Search Term  Advanced Search

Sign in | Get NEJM's E-Mail Table of Contents — Free | Subscribe

Previous Volume 324:150-154 January 17, 1991 Number 3 Next

	Add to Personal Archive Add to Citation Manager Notify a Friend E-mail When Cited PubMed Citation

Abstract

BACKGROUND. The antimalarial drug hydroxychloroquine is thought to be effective in controlling some of the manifestations of systemic lupus erythematosus, but its effectiveness has not been demonstrated conclusively. METHODS. We conducted a six-month, randomized, double-blind, placebo-controlled study of the effect of discontinuing hydroxychloroquine sulfate treatment in 47 patients with clinically stable systemic lupus erythematosus. The patients were randomly assigned to continue their same dose of hydroxychloroquine (n = 25) or to receive placebo (n = 22) for 24 weeks. Ten patients in each group were also taking prednisone. RESULTS. The relative risk of a clinical flare-up, defined as the development of specific clinical manifestations of systemic lupus erythematosus or an increase in their severity, was 2.5 times higher (95 percent confidence interval, 1.08 to 5.58) in the patients taking placebo than in those continuing to take hydroxychloroquine (16 of 22 patients vs. 9 of 25 had flare-ups), and the time to a flare-up was shorter (P = 0.02). The relative risk of a severe exacerbation of disease that required withdrawal from the study was 6.1 times higher (95 percent confidence interval, 0.72 to 52.44) for the patients taking placebo (5 of 22 patients vs. 1 of 25 had severe exacerbations of disease). Changes in the dose of prednisone were not different in the two groups. CONCLUSIONS. Patients with quiescent systemic lupus erythematosus who are taking hydroxychloroquine are less likely to have a clinical flare-up if they are maintained on the drug.

This article has been cited by other articles:

• Yuen, S. Y., Pope, J. E. (2008). Learning from past mistakes: assessing trial quality, power and eligibility in non-renal systemic lupus erythematosus randomized controlled trials. Rheumatology (Oxford) 47: 1367-1372 [Abstract] [Full Text]  
• Andrade, R M, Alarcon, G S, Gonzalez, L A, Fernandez, M, Apte, M, Vila, L M, McGwin, G Jr, Reveille, J D, for the LUMINA Study Group, (2008). Seizures in patients with systemic lupus erythematosus: data from LUMINA, a multiethnic cohort (LUMINA LIV). Ann Rheum Dis 67: 829-834 [Abstract] [Full Text]  
• Ruiz-Irastorza, G, Khamashta, M. (2008). Hydroxychloroquine: the cornerstone of lupus therapy. Lupus 17: 271-273  
• Siso, A, Ramos-Casals, M, Bove, A, Brito-Zeron, P, Soria, N, Munoz, S, Testi, A, Plaza, J, Sentis, J, Coca, A (2008). Previous antimalarial therapy in patients diagnosed with lupus nephritis: Influence on outcomes and survival. Lupus 17: 281-288 [Abstract]  
• Doria, A, Briani, C (2008). Lupus: improving long-term prognosis. Lupus 17: 166-170 [Abstract]  
• Bertsias, G, Ioannidis, J P A, Boletis, J, Bombardieri, S, Cervera, R, Dostal, C, Font, J, Gilboe, I M, Houssiau, F, Huizinga, T, Isenberg, D, Kallenberg, C G M, Khamashta, M, Piette, J C, Schneider, M, Smolen, J, Sturfelt, G, Tincani, A, van Vollenhoven, R, Gordon, C, Boumpas, D T (2008). EULAR recommendations for the management of systemic lupus erythematosus. Report of a Task Force of the EULAR Standing Committee for International Clinical Studies Including Therapeutics. Ann Rheum Dis 67: 195-205 [Abstract] [Full Text]  
• Petri, M. (2007). Disease activity assessment in SLE: do we have the right instruments?. Ann Rheum Dis 66: iii61-iii64 [Abstract] [Full Text]  
• Alarcon, G. S, McGwin, G., Bertoli, A. M, Fessler, B. J, Calvo-Alen, J., Bastian, H. M, Vila, L. M, Reveille, J. D, for the LUMINA Study Group, (2007). Effect of hydroxychloroquine on the survival of patients with systemic lupus erythematosus: data from LUMINA, a multiethnic US cohort (LUMINA L). Ann Rheum Dis 66: 1168-1172 [Abstract] [Full Text]  
• James, J., Kim-Howard, X., Bruner, B., Jonsson, M., McClain, M., Arbuckle, M., Walker, C., Dennis, G., Merrill, J., Harley, J. (2007). Hydroxychloroquine sulfate treatment is associated with later onset of systemic lupus erythematosus. Lupus 16: 401-409 [Abstract]  
• Sachet, J.C., Borba, E.F., Bonfa, E., Vinagre, C.G.C., Silva, V.M., Maranhao, R.C. (2007). Chloroquine increases low-density lipoprotein removal from plasma in systemic lupus patients. Lupus 16: 273-278 [Abstract]  
• Wozniacka, A, Lesiak, A, Narbutt, J, Kobos, J, Pavel, S, Sysa-Jedrzejowska, A (2007). Chloroquine treatment reduces the number of cutaneous HLA-DR+ and CD1a+ cells in patients with systemic lupus erythematosus. Lupus 16: 89-94 [Abstract]  
• Parke, A (2006). Drug exposure, pregnancy outcome and fetal and childhood development occurring in the offspring of mothers with systemic lupus erythematosus and other chronic autoimmune diseases. Lupus 15: 808-813 [Abstract]  
• Doria, A, Iaccarino, L, Arienti, S, Rampudda, M E, Canova, M G, Rondinone, R, Todesco, S (2006). Mycophenolate mofetil and systemic lupus erythematosus. Lupus 15: 44-54 [Abstract]  
• Fernandez, M, McGwin, G Jr., Bertoli, A M, Calvo-Alen, J, Vila, L M, Reveille, J D, Alarcon, G S, for the LUMINA Study Group, (2006). Discontinuation rate and factors predictive of the use of hydroxychloroquine in LUMINA, a multiethnic US cohort (LUMINA XL). Lupus 15: 700-704  
• Ruiz-Irastorza, G, Egurbide, M-V, Pijoan, J-I, Garmendia, M, Villar, I, Martinez-Berriotxoa, A, Erdozain, J-G, Aguirre, C (2006). Effect of antimalarials on thrombosis and survival in patients with systemic lupus erythematosus. Lupus 15: 577-583 [Abstract]  
• Kasitanon, N, Fine, D M, Haas, M, Magder, L S, Petri, M (2006). Hydroxychloroquine use predicts complete renal remission within 12 months among patients treated with mycophenolate mofetil therapy for membranous lupus nephritis. Lupus 15: 366-370 [Abstract]  
• Wozniacka, A, Lesiak, A, Narbutt, J, McCauliffe, D P, Sysa-Jedrzejowska, A (2006). Chloroquine treatment influences proinflammatory cytokine levels in systemic lupus erythematosus patients. Lupus 15: 268-275 [Abstract]  
• Kong, N. C. T. (2006). Pregnancy of a lupus patient--a challenge to the nephrologist. Nephrol Dial Transplant 21: 268-272 [Full Text]  
• Petri, M (2005). Lupus in Baltimore: evidence-based 'clinical pearls' from the Hopkins Lupus Cohort. Lupus 14: 970-973 [Abstract]  
• Ostensen, M (2004). Disease specific problems related to drug therapy in pregnancy. Lupus 13: 746-750 [Abstract]  
• Schiffenbauer, J, Simon, L S (2004). Randomized controlled trials in systemic lupus erythematosus: what has been done and what do we need to do?. Lupus 13: 398-405 [Abstract]  
• Borba, E F, Turrini-Filho, J R, Kuruma, K A., Bertola, C, Pedalini, M E., Lorenzi, M C, Bonfa, E (2004). Chloroquine gestational use in systemic lupus erythematosus: assessing the risk of child ototoxicity by pure tone audiometry. Lupus 13: 223-227 [Abstract]  
• Toubi, E, Kessel, A, Rosner, I, Rozenbaum, M, Lorber, M, Paran, D, Sabo, E, Golan, T D (2003). Quinacrine added to ongoing therapeutic regimens attenuates anticardiolipin antibody production in SLE. Lupus 12: 297-301 [Abstract]  
• Ioannou, Y, Isenberg, D A (2002). Current concepts for the management of systemic lupus erythematosus in adults: a therapeutic challenge. Postgrad. Med. J. 78: 599-606 [Abstract] [Full Text]  
• Molad, Y, Gorshtein, A, Wysenbeek, A J, Guedj, D, Majadla, R, Weinberger, A, Amit-Vazina, M (2002). Protective effect of hydroxychloroquine in systemic lupus erythematosus. Prospective long-term study of an Israeli cohort{. Lupus 11: 356-361 [Abstract]  
• Cortes-Hernandez, J., Ordi-Ros, J., Paredes, F., Casellas, M., Castillo, F., Vilardell-Tarres, M. (2002). Clinical predictors of fetal and maternal outcome in systemic lupus erythematosus: a prospective study of 103 pregnancies. Rheumatology (Oxford) 41: 643-650 [Abstract] [Full Text]  
• Piette, J-C, Sbai, A, Frances, C (2002). Warning: thalidomide-related thrombotic risk potentially concerns patients with lupus. Lupus 11: 67-70  
• Wozniacka, A, Carter, A, Mccauliffe, D P (2002). Antimalarials in cutaneous lupus erythematosus: mechanisms of therapeutic benefit. Lupus 11: 71-81 [Abstract]  
• Wallace, D J (2001). Antimalarials--the 'real' advance in lupus. Lupus 10: 385-387  
• Levy, R A, Vilela, V S, Cataldo, M J, Ramos, R C, Duarte, J L., Tura, B R, Albuquerque, E M., Jesus, N R (2001). Hydroxychloroquine (HCQ) in lupus pregnancy: double-blind and placebo-controlled study. Lupus 10: 401-404 [Abstract]  
• D'Cruz, D (2001). Antimalarial therapy: a panacea for mild lupus?. Lupus 10: 148-151 [Abstract]  
• Ting, W W, Sontheimer, R D (2001). Local therapy for cutaneous and systemic lupus erythematosus: practical and theoretical considerations. Lupus 10: 171-184 [Abstract]  
• Mok, C C, Wong, R W S (2001). Pregnancy in systemic lupus erythematosus. Postgrad. Med. J. 77: 157-165 [Abstract] [Full Text]  
• Rojas-Serrano, J, Cardiel, M H (2000). Lupus patients in an emergency unit. Causes of consultation, hospitalization and outcome. A cohort study. Lupus 9: 601-606 [Abstract]  
• Strand, V, Gladman, D, Isenberg, D, Petri, M, Smolen, J, Tugwell, P (2000). Endpoints: consensus recommendations from OMERACT IV. Lupus 9: 322-327 [Abstract]  
• Toubi, E, Rosner, I, Rozenbaum, M, Kessel, A, Golan, T D (2000). The benefit of combining hydroxychloroquine with quinacrine in the treatment of SLE patients. Lupus 9: 92-95 [Abstract]  
• Gaubitz, M., Schorat, A., Schottel, H., Kern, P., Domschke, W. (1999). Mycophenolate mofetil for the treatment of systemic lupus erythematosus: an open pilot trial. Lupus 8: 731-736 [Abstract]  
• Liang, M. H, Corzillius, M., Bae, S.-C., Fortin, P., Esdaile, J. M, Abrahamowicz, M. (1999). A conceptual framework for clinical trials in SLE and other multisystem diseases. Lupus 8: 570-580  
• Siegel, J N (1999). Development of an FDA guidance document for clinical trials in SLE. Lupus 8: 581-585 [Abstract]  
• Moore, A. D, Joseph, L. (1999). Sample size considerations for superiority trials in systemic lupus erythematosus (SLE). Lupus 8: 612-619 [Abstract]  
• Corzillius, M, Bae, S-C (1999). Methodological issues of corticosteroid use in SLE clinical trials. Lupus 8: 692-697 [Abstract]  
• Petri, M. (1998). Hydroxychloroquine: past, present, future. Lupus 7: 65-67  
• The Canadian Hydroxychloroquine Study Group, , Tsakonas, E, Joseph, L, Esdaile, J M, Choquette, D, Senecal, J-L, Cividino, A, Danoff, D, Osterland, C K, Yeadon, C, Smith, C D (1998). A Long-Term Study of Hydroxychloroquine Withdrawal on Exacerbations in Systemic Lupus Erythematosus. Lupus 7: 80-85 [Abstract]  
• (1996). Systemic lupus erythematosus. DTB 34: 20-23 [Abstract] [Full Text]  
• Martinez-Taboada, V., Blanco Alonso, R., Armona, J., Femandez-Sueiro, J., Gonzalez Vela, C., Rodriguez-Valverde, V. (1996). Mononeuritis multiplex in systemic lupus erythematosus: response to pulse intravenous cyclophosphamide. Lupus 5: 74-76 [Abstract]  
• Abu El-Asrar, A. M, Naddaf, H. O, Al-Momen, A.-K., Al-Balla, S. R (1995). Systemic lupus erythematosus flare-up manifesting as a cilioretinal artery occlusion. Lupus 4: 158-160 [Abstract]  
• Derksen, R. H.W.M., Bruinse, H. W., de Groot, P. G., Kater, L. (1994). Pregnancy in Systemic Lupus Erythematosus: a Prospective Study. Lupus 3: 149-155 [Abstract]  
• Nived, O., Johansen, P. B., Sturfelt, G. (1993). Standardized Ultraviolet-A Exposure Provokes Skin Reaction in Systemic Lupus Erythematosus. Lupus 2: 247-250 [Abstract]  
• Rothe, M. J., Kerdel, F. A. (1992). Review: Treatment of Cutaneous Lupus Erythematosus. Lupus 1: 351-356 [Abstract]  
• (1991). HYDROXYCHLOROQUINE IS EFFECTIVE MAINTENANCE THERAPY FOR STABLE LUPUS. JWatch General 1991: 2-2 [Full Text]